Long O
- O
term O
outcomes O
with O
intensive O
induction O
chemotherapy O
( O
carboplatin B-DESC
, I-DESC
bleomycin I-DESC
, I-DESC
vincristine I-DESC
and I-DESC
cisplatin I-DESC
/ I-DESC
bleomycin I-DESC
, I-DESC
etoposide I-DESC
and I-DESC
cisplatin I-DESC
) O
and O
standard O
bleomycin B-DESC
, I-DESC
etoposide I-DESC
and I-DESC
cisplatin I-DESC
in O
poor O
prognosis O
germ O
cell O
tumours O
: O
A O
randomised B-STYPE
phase I-STYPE
II I-STYPE
trial I-STYPE
( O
ISRCTN53643604 O
) O
Long O
- O
term O
outcomes O
with O
intensive O
induction O
chemotherapy O
( O
carboplatin B-DESC
, I-DESC
bleomycin I-DESC
, I-DESC
vincristine I-DESC
and I-DESC
cisplatin I-DESC
/ I-DESC
bleomycin I-DESC
, I-DESC
etoposide I-DESC
and I-DESC
cisplatin I-DESC
) O
and O
standard O
bleomycin B-DESC
, I-DESC
etoposide I-DESC
and I-DESC
cisplatin I-DESC
in O
poor O
prognosis O
germ O
cell O
tumours O
: O
A O
randomised B-STYPE
phase I-STYPE
II I-STYPE
trial I-STYPE
( O
ISRCTN53643604 O
) O
31 O
January O
2020 O
31 O
January O
2020 O
FayHCafferty B-AUTH

Long O
- O
term O
outcomes O
with O
intensive O
induction O
chemotherapy O
( O
carboplatin B-DESC
, I-DESC
bleomycin I-DESC
, I-DESC
vincristine I-DESC
and I-DESC
cisplatin I-DESC
/ I-DESC
bleomycin I-DESC
, I-DESC
etoposide I-DESC
and I-DESC
cisplatin I-DESC
) O
and O
standard O
bleomycin B-DESC
, I-DESC
etoposide I-DESC
and I-DESC
cisplatin I-DESC
in O
poor O
prognosis O
germ O
cell O
tumours O
: O
A O
randomised B-STYPE
phase I-STYPE
II I-STYPE
trial I-STYPE
( O
ISRCTN53643604 O
) O
31 O
January O
2020 O
10.1016 O
/ O
j.ejca.2019.12.028 O

Long O
- O
term O
outcomes O
with O
intensive O
induction O
chemotherapy O
( O
carboplatin B-DESC
, I-DESC
bleomycin I-DESC
, I-DESC
vincristine I-DESC
and I-DESC
cisplatin I-DESC
/ I-DESC
bleomycin I-DESC
, I-DESC
etoposide I-DESC
and I-DESC
cisplatin I-DESC
) O
and O
standard O
bleomycin B-DESC
, I-DESC
etoposide I-DESC
and I-DESC
cisplatin I-DESC
in O
poor O
prognosis O
germ O
cell O
tumours O
: O
A O
randomised B-STYPE
phase I-STYPE
II I-STYPE
trial I-STYPE
( O
ISRCTN53643604 O
) O
FayHCafferty B-AUTH

UK O
Hucknall O
Road O
NG5 O
1PB O
Nottingham O
UK O
SallyPStenning B-AUTH
SallyPStenning B-AUTH
Sally B-AUTH
P I-AUTH
Stenning I-AUTH
RobertAHuddart B-AUTH
RobertAHuddart B-AUTH
Robert B-AUTH
A I-AUTH
Huddart I-AUTH
UCL O
90 O
High O
Holborn O
WC1V O
6LJ O
London O
UK O
UCL O
90 O
High O
Holborn O
WC1V O
6LJ O
London O

UK O
90 O
High O
Holborn O
WC1V O
6LJ O
London O
UK O
The O
Institute O
of O
Cancer O
Research O
and O
the O
Royal O
Marsden O
NHS O
Foundation O
Trust O
Downs O
Road O
SM2 O
5PT O
Sutton O

UK O
90 O
High O
Holborn O
2nd O
Floo O
WC1V O
6LJ O
London O
UK O
Long O
- O
term O
outcomes O
with O
intensive O
induction O
chemotherapy O
( O
carboplatin B-DESC
, I-DESC
bleomycin I-DESC
, I-DESC
vincristine I-DESC
and I-DESC
cisplatin I-DESC
/ I-DESC
bleomycin I-DESC
, I-DESC
etoposide I-DESC
and I-DESC
cisplatin I-DESC
) O
and O
standard O
bleomycin B-DESC
, I-DESC
etoposide I-DESC
and I-DESC
cisplatin I-DESC
in O
poor O
prognosis O
germ O
cell O
tumours O
: O
A O
randomised B-STYPE
phase I-STYPE
II I-STYPE
trial I-STYPE
( O
ISRCTN53643604 O
) O
31 O
January O
2020 O
31 O
January O
2020 O
31 O
January O
2020 O
10.1016 O
/ O
j.ejca.2019.12.028 O
Received O
6 O
October O
2019 O
; O
received O
in O
revised O
form O
19 O
December O
2019 O
; O
accepted O
21 O
December O
2019 O

BEP O
( O
bleomycin O
, O
etoposide O
and O
cisplatin O
) O
chemotherapy O
has O
been O
the O
standard O
treatment O
for O
metastatic O
germ O
cell O
tumours O
( O
GCTs O
) O
for O
many O
years O
and O
is O
successful O
for O
many O
patients O
. O
However O
, O
there O
is O
a O
wellcharacterised O
poor O
prognosis O
group O
for O
whom O
cure O
rates O
remain O
less O
than O
50 O
% O
[ O
1 O
] O
. O
Attempts O
to O
improve O
on O
this O
have O
, O
to O
date O
, O
been O
largely O
unsuccessful O
[ O
2 O
] O
. O
Most O
recently O
, O
the O
GETUG O
( O
Genito O
- O
Urinary O
Group O
of O
the O
French O
Federation O
of O
Cancer O
Centres O
) O
13 O
trial O
suggested O
that O
dose O
intensification O
based O
on O
inadequate O
marker O
decline O
during O
early O
treatment O
may O
be O
beneficial O
[ O
3 O
] O
. O

TE23 O
( O
ISRCTN O
53643604 O
) O
was O
a O
randomised O
, O
phase O
II O
trial O
aiming O
to O
assess O
the O
efficacy O
and O
safety O
of O
a O
dose O
- O
intense O
regimen O
, O
CBOP O
/ O
BEP O
( O
carboplatin O
, O
bleomycin O
, O
vincristine O
, O
cisplatin O
/ O
BEP O
) O
, O
in O
these O
patients O
. O
The O
regimen O
, O
originally O
developed O
by O
the O
Royal O
Marsden O
Testicular O
Tumour O
Unit O
based O
on O
Wettlaufer O
et O
al O
. O
[ O
4 O
] O
, O
features O
early O
dose O
- O
intensity,{super O
comma O
? O
} O
use O
of O
infusional O
bleomycin O
( O
rather O
than O
bolus O
injections O
) O
and O
BEP O
with O
reduced O
bleomycin O
dose O
in O
the O
second O
stage O
. O

In O
the O
primary O
analysis O
, O
CBOP O
/ O
BEP O
met O
response O
targets O
: O
74 O
% O
of O
patients O
achieved O
a O
complete O
response O
or O
partial O
response O
marker O
negative O
( O
90 O
% O
CI O
: O
61%e85 O
% O
; O
primary O
outcome O
) O
[ O
2 O
] O
. O
The O
trial O
was O
not O
powered O
to O
compare O
arms O
but O
BEP O
response O
rate O
e O
used O
as O
a O
benchmark O
e O
was O
as O
expected O
at O
61 O
% O
( O
90 O
% O
CI O
: O
48 O
% O
, O
73 O
% O
) O
. O
Acute O
toxicity O
, O
particularly O
haematological O
, O
was O
higher O
with O
CBOP O
/ O
BEP O
. O

Here O
, O
we O
report O
long O
- O
term O
data O
from O
the O
trial O
, O
including O
efficacy O
outcomes O
and O
late O
toxicity O
. O
In O
addition O
, O
the O
role O
of O
early O
marker O
decline O
for O
predicting O
long O
- O
term O
outcomes O
is O
considered O
. O

Eligible O
patients O
were O
! O
16 O
years O
with O
extracranial O
GCT O
and O
at O
least O
one O
International O
Germ O
Cell O
Cancer O
Collaborative O
Group O
( O
IGCCCG O
) O
poor O
prognosis O
feature O
( O
mediastinal O
primary O
, O
non O
- O
pulmonary O
visceral O
metastases O
, O
AFP O
[ O
alpha O
fetaprotein O
] O
> O
10,000 O
ng O
/ O
ml O
, O
HCG O
[ O
human O
chorionic O
gonadotropin O
] O
> O
50,000iu O
/ O
l O
or O
LDH O
[ O
lactase O
dehydrogenase O
] O
> O
10Ã‚ O
upper O
limit O
of O
normal O
[ O
ULN O
] O
) O
. O
Diagnoses O
were O
based O
on O
histology O
; O
or O
elevated O
AFP O
and/or O
HCG O
in O
a O
patient O
with O
a O
testicular O
tumour O
; O
or O
unequivocally O
elevated O
markers O
( O
AFP>1000 O
ng O
/ O
ml O
or O
HCG>5000iu O
/ O
l O
) O
in O
men O
aged O
< O
45 O
years O
without O
a O
testis O
tumour O
but O
with O
an O
otherwise O
appropriate O
clinical O
picture O
. O
Applicable O
regulatory O
and O
ethics O
approvals O
, O
and O
written O
informed O
consent O
, O
were O
obtained O
. O

This O
was O
an O
open B-STYPE
- I-STYPE
label I-STYPE
, I-STYPE
parallel I-STYPE
, I-STYPE
phase I-STYPE
II I-STYPE
, I-STYPE
multicentre I-STYPE
, I-STYPE
UK I-STYPE
trial I-STYPE
with O
randomisation O
( O
1:1 O
) O
to O
BEP B-DESC
or O
CBOP/ B-DESC
BEP I-DESC
. O
Eligible O
patients O
not O
deemed O
fit O
enough O
to O
receive O
protocol O
treatment O
( O
by O
the O
treating O
investigator O
) O
could O
be O
stabilised O
with O
low O
- O
dose O
chemotherapy O
( O
normally O
20 O
mg O
/ O
m O
2 O
of O
cisplatin O
20 O
mg O
/ O
m O
or O
carboplatin O
AUC3 O
and O
etoposide O
or O
vincristine O
for O
two O
days O
) O
before O
enrolment O
. O
Randomisation O
at O
the O
coordinating O
trial O
unit O
( O
accessible O
by O
telephone O
to O
recruiting O
teams O
) O
used O
minimisation O
based O
on O
preprotocol O
chemotherapy O
, O
primary O
tumour O
site O
, O
centre O
and O
a O
random O
element O
. O

The O
control O
arm O
comprised O
4 B-DOSAGE
cycles I-DOSAGE
of I-DOSAGE
Indiana I-DOSAGE
- I-DOSAGE
style I-DOSAGE
5day I-DOSAGE
BEP  B-DESC
[ B-DOSAGE
5 I-DOSAGE
] I-DOSAGE
over I-DOSAGE
12 I-DOSAGE
weeks I-DOSAGE
: I-DOSAGE
100 I-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
of I-DOSAGE
etoposide B-DESC
and O
20 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
of O
cisplatin B-DESC
on B-DOSAGE
days I-DOSAGE
1e5 I-DOSAGE
of I-DOSAGE
each I-DOSAGE
cycle I-DOSAGE
and I-DOSAGE
12 I-DOSAGE
doses I-DOSAGE
of I-DOSAGE
30,000iu I-DOSAGE
of O
bleomycin B-DESC
weekly B-DOSAGE
. O
The O
CBOP/ B-DESC
BEP I-DESC
arm O
comprised O
6 B-DOSAGE
chemotherapy I-DOSAGE
cycles I-DOSAGE
over I-DOSAGE
15 I-DOSAGE
weeks I-DOSAGE
. O
At O
weeks B-DOSAGE
1 I-DOSAGE
and I-DOSAGE
3 I-DOSAGE
, I-DOSAGE
50 I-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
of O
cisplatin O
on B-DOSAGE
days I-DOSAGE
1 I-DOSAGE
and I-DOSAGE
2 I-DOSAGE
and I-DOSAGE
2 I-DOSAGE
mg I-DOSAGE
of O
vincristine O
and O
15000iu B-DOSAGE
of O
bleomycin O
on B-DOSAGE
day I-DOSAGE
1 I-DOSAGE
were I-DOSAGE
administered I-DOSAGE
. I-DOSAGE
At I-DOSAGE
weeks I-DOSAGE
2 I-DOSAGE
and I-DOSAGE
4 I-DOSAGE
, I-DOSAGE
40 I-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
of O
cisplatin O
, O
2 B-DOSAGE
mg I-DOSAGE
of O
vincristine O
and O
carboplatin O
AUC3 B-DOSAGE
all I-DOSAGE
on I-DOSAGE
day I-DOSAGE
1 I-DOSAGE
and I-DOSAGE
15000iu I-DOSAGE
of O
bleomycin O
by O
24-h B-DOSAGE
iv I-DOSAGE
infusion I-DOSAGE
on I-DOSAGE
days I-DOSAGE
1e5 I-DOSAGE
( I-DOSAGE
total I-DOSAGE
dose I-DOSAGE
75000iu I-DOSAGE
) I-DOSAGE
were O
administered O
. O
At O
weeks B-DOSAGE
5 I-DOSAGE
and I-DOSAGE
6 I-DOSAGE
, I-DOSAGE
2 I-DOSAGE
mg I-DOSAGE
of O
vincristine O
and O
15000iu B-DOSAGE
of O
bleomycin O
on B-DOSAGE
day I-DOSAGE
1 I-DOSAGE
were I-DOSAGE
administered I-DOSAGE
. I-DOSAGE
At I-DOSAGE
weeks I-DOSAGE
7e15 I-DOSAGE
, I-DOSAGE
3 I-DOSAGE
cycles I-DOSAGE
of O
Indiana O
- O
style O
BEP B-DESC
administered O
as O
for O
the O
control O
arm O
, O
except O
with O
modified O
bleomycin O
dose O
of O
15000iu B-DOSAGE
weekly I-DOSAGE
. O
Prophylactic O
granulocyte O
- O
colony O
stimulating O
factor O
( O
G O
- O
CSF O
) O
was O
mandated O
( O
in O
week O
five O
of O
CBOP B-DESC
/ I-DESC
BEP I-DESC
and O
during O
each O
BEP B-DESC
cycle O
in O
both O
arms O
) O
from O
January O
2008 O
following O
an O
Independent O
Data O
Monitoring O
Committee O
recommendation O
. O

Assessments O
and O
management O
during O
treatment O
have O
been O
reported O
previously O
[ O
2 O
] O
. O
The O
protocol O
specified O
a O
5-year O
follow O
- O
up O
period O
after O
randomisation O
. O
Follow O
- O
up O
assessments O
( O
clinical O
examination O
, O
chest O
xray O
and O
markers O
) O
were O
performed O
two O
- O
monthly O
in O
year O
one O
, O
3-monthly O
in O
year O
two O
and O
then O
six O
months O
once O
to O
5 O
years O
. O
Audiometry O
and O
lung O
function O
were O
assessed O
at O
12 O
months O
and O
semen O
analysis O
at O
24 O
months O
. O
Crosssectional O
imaging O
was O
performed O
at O
2e4 O
weeks O
after O
end O
of O
treatment O
. O
It O
was O
additionally O
performed O
to O
follow O
residual O
disease O
6-monthly O
until O
resolution O
( O
< O
1 O
cm O
) O
, O
resected O
or O
stable O
for O
1 O
year O
; O
2 O
months O
after O
surgical O
resection O
of O
tumour O
masses O
; O
and O
at O
the O
investigator O
's O
discretion O
. O
Surgical O
resection O
was O
advised O
for O
all O
non O
- O
resolving O
masses O
> O
1 O
cm O
. O
Management O
of O
disease O
progression O
was O
at O
the O
clinician O
's O
discretion O
. O
This O
analysis O
was O
planned O
when O
all O
of O
the O
follow O
- O
up O
was O
complete O
. O
For O
patients O
who O
were O
lost O
to O
follow O
- O
up O
, O
survival O
status O
was O
sought O
via O
general O
practitioners O
( O
GPs O
) O
. O

The O
primary O
outcome O
( O
reported O
previously O
) O
was O
favourable O
response O
rate O
: O
the O
proportion O
of O
patients O
achieving O
complete O
response O
( O
disappearance O
of O
all O
disease O
and O
normal O
tumour O
markers O
) O
or O
partial O
response O
( O
residual O
mass O
unresected O
) O
with O
negative O
markers O
. O

The O
current O
analysis O
focuses O
on O
secondary O
outcomes O
: O
progression B-METRIC
- I-METRIC
free I-METRIC
survival I-METRIC
( O
PFS B-METRIC
, O
time O
from O
randomisation O
until O
disease O
progression O
, O
relapse O
or O
death O
, O
with O
treatment O
failure O
considered O
to O
be O
an O
event O
, O
and O
censoring O
at O
the O
most O
recent O
assessment O
for O
eventfree O
patients O
) O
; O
overall O
survival O
( O
OS O
, O
time O
from O
randomisation O
until O
death O
from O
any O
cause O
, O
with O
censoring O
at O
the O
date O
last O
known O
to O
be O
alive O
) O
and O
toxicity O
( O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
( O
CTCAE O
) O
v3.0 O
) O
at O
12 O
months O
( O
Ã¾ O
/ O
Ã€ O
2 O
months O
) O
. O
Data O
on O
pulmonary O
and O
audiometry O
investigations O
performed O
at O
this O
time O
were O
insufficient O
. O

PFS B-METRIC
/ O
OS O
analyses O
were O
based O
on O
Kaplan O
- O
Meier O
curves O
and O
hazard O
ratios O
( O
HRs O
) O
derived O
from O
Cox O
regression O
models O
with O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
. O
Exploratory O
analyses O
considered O
the O
impact O
of O
IGCCCG O
poor O
risk O
features O
[ O
1 O
] O
, O
receipt O
of O
stabilising O
chemotherapy O
and O
early O
marker O
decline O
, O
with O
p O
< O
0.1 O
( O
2-sided O
) O
regarded O
as O
significant O
. O
Marker O
decline O
was O
classified O
based O
on O
the O
GETUG13 O
algorithm O
[ O
3,6 O
] O
, O
considering O
AFP O
and O
HCG O
values O
after O
one O
BEP O
cycle O
( O
approximately O
day O
21 O
) O
in O
the O
BEP B-DESC
arm I-DESC
or O
after O
two O
CBOP B-DESC
cycles O
( O
approximately O
day O
28 O
; O
with O
day O
14 O
values O
used O
if O
the O
later O
value O
was O
not O
available O
) O
in O
the O
CBOP B-DESC
/ I-DESC
BEP I-DESC
arm I-DESC
( O
appendix O
A O
) O
. O
In O
multivariable O
models O
, O
treatment O
effect O
was O
adjusted O
for O
any O
factors O
with O
p O
< O
0.1 O
in O
univariate O
models O
. O
Power O
was O
limited O
, O
particularly O
for O
OS O
, O
where O
number O
of O
events O
was O
small O
. O
All O
randomized O
patients O
were O
included O
on O
an O
intent O
- O
to O
- O
treat O
basis O
with O
the O
exception O
of O
models O
incorporating O
early O
marker O
decline O
, O
where O
3 O
patients O
who O
stopped O
treatment O
before O
the O
relevant O
marker O
assessment O
were O
excluded O
. O
Subgroup O
analyses O
considered O
the O
impact O
of O
early O
marker O
decline O
in O
the O
BEP B-DESC
arm I-DESC
and O
in O
those O
who O
did O
not O
receive O
stabilising O
chemotherapy O
. O

Between O
June O
2005 O
and O
December O
2009 O
, O
89 O
patients O
were O
enrolled O
from O
16 O
UK O
centres O
( O
recruiting O
between O
1 O
and O
15 O
patients O
each O
, O
median O
5 O
) O
; O
43 O
of O
them O
were O
randomised O
to O
CBOP B-DESC
/ I-DESC
BEP I-DESC
( O
Fig O
. O
1 O
) O
. O
The O
mean O
age O
was O
30 O
years O
( O
range O
16e68 O
) O
, O
and O
18 O
patients O
( O
20 O
% O
) O
had O
mediastinal O
primary O
tumours O
. O
Fifty O
- O
three O
patients O
( O
60 O
% O
) O
had O
diagnosis O
confirmed O
histologically O
and O
36 O
( O
40 O
% O
) O
based O
on O
markers/ O
clinical O
picture O
. O
Sixty O
- O
four O
patients O
( O
72 O
% O
) O
had O
not O
undergone O
orchidectomy O
at O
the O
time O
of O
trial O
registration O
. O
Twenty O
- O
four O
patients O
( O
27 O
% O
) O
had O
low O
- O
dose O
chemotherapy O
for O
stabilisation O
. O
IGCCCG O
poor O
prognosis O
features O
and O
receipt O
of O
stabilising O
chemotherapy O
were O
similar O
between O
arms O
( O
Table O
1 O
) O
. O
Details O
of O
treatment O
and O
acute O
toxicity O
have O
been O
reported O
previously O
: O
completion O
rates O
were O
similarly O
high O
in O
the O
two O
arms O
( O
41/46 O
, O
89 O
% O
for O
BEP B-DESC
; O
40/ O
43 O
, O
93 O
% O
CBOP B-DESC
/ I-DESC
BEP I-DESC
) O
; O
rates O
of O
CTCAE O
grade O
! O
3 O
symptoms O
were O
higher O
with O
CBOP B-DESC
/ I-DESC
BEP I-DESC
( O
95 O
% O
vs O
63 O
% O
with O
BEP B-DESC
) O
, O
largely O
because O
of O
haematological O
toxicity O
. O

Median O
follow O
- O
up O
was O
63 O
months O
e O
similar O
between O
arms O
. O
All O
surviving O
patients O
had O
a O
minimum O
58-month O
follow O
- O
up O
, O
with O
the O
exception O
of O
6 O
who O
were O
lost O
to O
follow O
- O
up O
( O
4 O
BEP B-DESC
, O
2 O
CBOP B-DESC
/ I-DESC
BEP I-DESC
) O
. O
Of O
these O
, O
2 O
had O
had O
progression O
events O
( O
1 O
BEP B-DESC
treatment O
failure O
, O
with O
38month O
post O
- O
failure O
follow O
- O
up O
; O
1 O
progression O
following O
CBOP B-DESC
/ I-DESC
BEP I-DESC
, O
with O
9 O
months O
follow O
- O
up O
thereafter O
) O
. O
Survival O
status O
at O
! O
5 O
years O
was O
obtained O
through O
GPs O
for O
these O
2 O
patients O
, O
and O
for O
a O
furtherBEP B-DESC
patient O
who O
was O
lost O
to O
follow O
- O
up O
. O
Fig O
. O
1 O
. O
Flow O
of O
participants O
through O
the O
trial O
. O
a O
2 O
of O
these O
patients O
had O
already O
had O
a O
progression O
event O
at O
the O
time O
of O
loss O
to O
follow O
- O
up O
( O
1 O
BEP B-DESC
and O
1 O
CBOP B-DESC
/ I-DESC
BEP I-DESC
, O
with O
38 O
and O
9 O
month O
postprogression O
follow O
- O
up O
, O
respectively O
) O
and O
so O
contribute O
complete O
data O
to O
the O
PFS B-METRIC
analysis O
; O
in O
addition O
, O
survival O
information O
at O
! O
5 O
years O
was O
obtained O
from O
GPs O
for O
the O
2 O
patients O
who O
had O
already O
progressed O
and O
a O
further O
1 O
BEP B-DESC
patient O
. O
b O
3 O
patients O
( O
2 O
BEP B-DESC
, O
1 O
CBOP B-DESC
/ I-DESC
BEP I-DESC
) O
are O
excluded O
from O
models O
incorporating O
marker O
decline O
because O
they O
only O
received O
one O
cycle O
of O
treatment O
in O
the O
trial O
and O
, O
therefore O
, O
did O
not O
have O
the O
relevant O
marker O
assessment O
for O
calculation O
of O
time O
to O
normalisation O
. O
In O
addition O
, O
analyses O
of O
12-month O
toxicity O
are O
restricted O
to O
surviving O
patients O
( O
33 O
BEP B-DESC
, O
32 O
CBOP B-DESC
/ I-DESC
BEP I-DESC
) O
with O
follow O
- O
up O
assessment O
data O
between O
10 O
and O
14 O
months O
after O
randomisation O
. O

Time O
to O
normalisation O
could O
not O
be O
calculated O
for O
3 O
patients O
( O
2 O
BEP B-DESC
, O
1 O
CBOP B-DESC
/ I-DESC
BEP I-DESC
) O
who O
only O
received O
one O
cycle O
of O
treatment O
in O
the O
trial O
and O
so O
did O
not O
have O
the O
relevant O
marker O
assessment O
. O
Sixty O
of O
eighty O
- O
six O
( O
70 O
% O
) O
of O
patients O
had O
unfavourable O
marker O
decline O
, O
and O
this O
was O
similar O
in O
the O
two O
arms O
( O
BEP B-DESC
: O
31/44 O
, O
70.5 O
% O
, O
90 O
% O
CI O
: O
57.2%e81.6 O
% O
; O
CBOP B-DESC
/ I-DESC
BEP I-DESC
: O
29/42 O
, O
69.0 O
% O
, O
90 O
% O
CI O
55:.4%e80.6 O
% O
) O
. O
As O
might O
be O
expected O
, O
high O
baseline O
AFP O
or O
HCG O
was O
correlated O
with O
unfavourable O
marker O
decline O
. O
The O
reverse O
trend O
was O
seen O
for O
LDH O
e O
a O
small O
number O
of O
patients O
had O
high O
( O
> O
10 O
ULN O
) O
LDH O
values O
, O
and O
these O
patients O
were O
more O
likely O
to O
have O
favourable O
marker O
decline O
. O
There O
were O
no O
other O
associations O
between O
IGCCCG O
factors O
or O
receipt O
of O
stabilising O
chemotherapy O
and O
marker O
decline O
( O
appendix O
B O
) O
. O

There O
were O
48 O
PFS B-METRIC
events I-METRIC
( O
29 B-RESULTS
BEP B-DESC
, O
19 B-RESULTS
CBOP B-DESC
/ I-DESC
BEP I-DESC
) O
, O
and O
median B-METRIC
PFS I-METRIC
was O
30 B-RESULTS
months I-RESULTS
( O
6 B-RESULTS
months I-RESULTS
in O
the O
BEP B-DESC
arm I-DESC
, O
not O
yet O
reached O
in O
the O
CBOP B-DESC
/ I-DESC
BEP I-DESC
arm O
) O
. O
Estimated O
3year B-METRIC
PFS I-METRIC
was O
38.7 B-RESULTS
% I-RESULTS
( I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
: I-RESULTS
24.7%e52.4 I-RESULTS
% I-RESULTS
) I-RESULTS
in O
the O
BEP B-DESC
arm I-DESC
and O
55.7 B-RESULTS
% I-RESULTS
( I-RESULTS
39.7%e69.0 I-RESULTS
% I-RESULTS
) I-RESULTS
for O
the O
CBOP B-DESC
/ I-DESC
BEP I-DESC
arm O
; O
hazard B-RESULTS
ratio I-RESULTS
( I-RESULTS
HR I-RESULTS
) I-RESULTS
Z I-RESULTS
0.59 I-RESULTS
( I-RESULTS
0.33e1.06 I-RESULTS
) I-RESULTS
, I-RESULTS
p I-RESULTS
Z I-RESULTS
0.079 I-RESULTS
( O
Fig O
. O
2a O
) O
. O
Rates O
remained O
the O
same O
at O
5 O
years O
. O

There O
were O
37 O
deaths O
( O
21 O
BEP B-DESC
, O
16 O
CBOP B-DESC
/ I-DESC
BEP I-DESC
) O
. O
Median O
survival O
time O
was O
just O
less O
than O
6 O
years O
in O
the O
BEP B-DESC
arm I-DESC
and O
had O
not O
yet O
been O
reached O
for O
the O
CBOP/ B-DESC
BEP I-DESC
arm I-DESC
. O
Estimated O
3-year O
OS O
was O
58.5 O
% O
( O
43.0%e O
71.2 O
% O
) O
in O
the O
BEP B-DESC
arm I-DESC
and O
65.0 O
% O
( O
48.8%e77.2 O
% O
) O
for O
the O
CBOP B-DESC
/ I-DESC
BEP I-DESC
arm I-DESC
; O
HR O
Z O
0.79 O
( O
95 O
% O
CI O
: O
0.41 O
to O
1.52 O
) O
, O
p O
Z O
0.49 O
( O
Fig O
. O
2b O
) O
. O

Estimated O
3-year B-METRIC
PFS I-METRIC
was O
higher O
in O
the O
group O
with O
unfavourable O
marker O
decline O
compared O
with O
those O
with O
favourable O
decline O
, O
though O
this O
trend O
was O
non O
- O
significant O
( B-RESULTS
51.7 I-RESULTS
% I-RESULTS
vs I-RESULTS
41.0 I-RESULTS
% I-RESULTS
, I-RESULTS
HR I-RESULTS
Z I-RESULTS
0.82 I-RESULTS
, I-RESULTS
p I-RESULTS
Z I-RESULTS
0.54 I-RESULTS
) I-RESULTS
. O
Results O
were O
similar O
in O
the O
subgroup O
who O
did O
not O
receive O
stabilising O
chemotherapy O
and O
in O
the O
subgroup O
of O
BEP B-DESC
patients O
. O

In O
univariate O
models O
, O
receipt O
of O
stabilising O
chemotherapy O
was O
associated O
with O
poorer O
PFS B-METRIC
( O
Table O
2 O
) O
. O
No O
significant O
associations O
were O
observed O
for O
IGCCCG O
poor O
risk O
factors O
, O
although O
there O
were O
non O
- O
significant O
negative O
trends O
associated O
with O
mediastinal O
primary O
site O
and O
multiple O
IGCCCG O
poor O
prognosis O
features O
. O
Treatment O
effect O
remained O
similar O
after O
adjustment O
for O
stabilising O
chemotherapy O
( O
Table O
2 O
) O
. O

Estimated O
3-year O
OS O
was O
higher O
in O
the O
group O
with O
unfavourable O
marker O
decline O
compared O
with O
those O
with O
favourable O
decline O
, O
although O
this O
was O
non O
- O
significant O
because O
of O
the O
low O
power O
of O
the O
model O
( O
66.7 O
% O
vs O
57.7 O
% O
, O
HR O
Z O
0.59 O
, O
p O
Z O
0.14 O
) O
. O
Results O
were O
similar O
in O
the O
two O
subgroup O
analyses O
. O

Results O
for O
univariate O
and O
multivariable O
models O
for O
OS O
were O
similar O
to O
those O
for O
PFS B-METRIC
e O
the O
only O
significant O
associations O
were O
for O
receipt O
of O
stabilising O
chemotherapy O
and O
mediastinal O
primary O
tumours O
( O
appendix O
C O
) O
. O
Treatment O
effect O
remained O
similar O
after O
adjustment O
for O
these O
factors O
. O

At O
12 O
months O
, O
there O
were O
65 O
surviving O
patients O
( O
33 O
BEP B-DESC
, O
32 O
CBOP B-DESC
/ I-DESC
BEP I-DESC
) O
, O
of O
which O
11 O
( O
7 O
BEP B-DESC
, O
4 O
CBOP B-DESC
/ I-DESC
BEP I-DESC
) O
had O
active O
disease O
. O
Burden O
of O
toxicity O
was O
similarly O
low O
in O
both O
arms O
( O
Table O
3 O
) O
. O
CTCAE O
grade O
! O
3 O
symptoms O
were O
reported O
in O
five O
patients O
in O
the O
BEP B-DESC
arm I-DESC
, O
all O
of O
whom O
had O
recently O
undergone O
further O
subsequent O
chemotherapy O
, O
and O
so O
symptoms O
may O
have O
been O
related O
to O
that O
treatment O
( O
or O
to O
active O
disease O
) O
. O

Thirty O
- O
five O
patients O
relapsed O
or O
their O
disease O
progressed O
during O
the O
trial O
( O
22 O
BEP B-DESC
, O
13 O
CBOP B-DESC
/ I-DESC
BEP I-DESC
) O
, O
including O
all O
patients O
with O
a O
treatment O
failure O
. O
Thirty O
patients O
( O
20 O
BEP B-DESC
, O
10 O
CBOP B-DESC
/ I-DESC
BEP I-DESC
) O
received O
treatment O
for O
relapse O
. O
Of O
the O
remaining O
five O
, O
three O
died O
around O
the O
time O
of O
diagnosis O
of O
relapse O
/ O
progression O
; O
one O
was O
felt O
not O
to O
be O
fit O
enough O
for O
salvage O
treatment O
and O
died O
two O
months O
later O
; O
and O
the O
remaining O
patient O
did O
not O
require O
further O
treatment O
and O
remained O
alive O
at O
the O
end O
of O
the O
followup O
. O
Of O
those O
treated O
, O
all O
but O
5 O
received O
combination O
chemotherapy O
( O
sometimes O
alongside O
radiotherapy O
or O
surgery O
) O
, O
most O
commonly O
paclitaxel O
, O
ifosfamide O
and O
cisplatin O
( O
TIP O
) O
( O
13 O
patients O
) O
, O
but O
a O
range O
of O
other O
regimens O
were O
used O
. O
Only O
1 O
patient O
( O
BEP B-DESC
arm I-DESC
) O
had O
a O
complete O
response O
and O
9 O
( O
7 O
BEP B-DESC
, O
2 O
CBOP B-DESC
/ I-DESC
BEP I-DESC
) O
had O
a O
partial O
response O
with O
negative O
markers O
. O

CBOP B-DESC
/ I-DESC
BEP I-DESC
has O
shown O
promise O
for O
treating O
men O
with O
poor O
prognosis O
GCT O
in O
a O
randomised B-STYPE
, I-STYPE
phase I-STYPE
II I-STYPE
trial I-STYPE
e O
response O
targets O
were O
met O
, O
and O
a O
PFS B-METRIC
benefit O
is O
suggested O
. O
Impact O
on O
survival O
is O
less O
clear O
and O
will O
be O
influenced O
by O
subsequent O
treatment O
. O
The O
regimen O
warrants O
study O
in O
a O
phase O
III O
trial O
. O